Negev Capital
Cayman Islandsnegevcap.com
Overview
Negev Capital is a venture capital firm that invests in early-stage companies developing novel drugs and medical interventions based on psychedelic compounds for neuropsychiatric disorders. The firm focuses on companies in the pre-clinical and Phase 1 stages of development, aiming to support the responsible, medical use of psychedelic medication. Their first fund, "Fund One", closed at over $30 million and is fully invested across 27 companies. The firm targets companies in the USA, Canada, Europe, and Israel.
Portfolio Companies
8
Website
negevcap.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Reconnect Labs | Aug 2025 | Series A | Co-investor |
| Gilgamesh Pharmaceuticals | Dec 2022 | Series B | Co-investor |
| Xylo Bio | Oct 2022 | Seed | Co-investor |
| Mindstate Design Labs | Feb 2022 | Seed | Co-investor |
| Mindstate Group | Feb 2022 | Seed | Co-investor |
Key People
George Kikvadze
Limited Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
